Bimatoprost
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Bimatoprost.png | |
| Bimatoprost
| |
| Systematic (IUPAC) name | |
| 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide | |
| Identifiers | |
| CAS number | |
| ATC code | S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C25H37NO4 |
| Mol. mass | 415.566 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Topical (eye drops) |
Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.[1] It is known by the brand name of Lumigan in USA, manufactured by Allergan Inc. Bimatoprost ophthalmic solution 0.03% is a synthetic prostamide analog with ocular hypotensive activity. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[1E,3S) -3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]- 5-N-ethylheptenamide, and its molecular weight is 415.58. Its molecular formula is C25H37NO4.[1]
Side effects
Possible side effects of this medication are:
- May cause blurred vision;
- May cause eyelid redness;
- May permanently darken eyelashes;
- May cause eye discomfort;
- May eventually cause permanent darkening of the iris to brown (heterochromia).
- May cause a temporary burning sensation during use.
- May cause thickening of the eyelashes.
References
- Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188-93. PMID 16808680.
- Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klin Monatsbl Augenheilkd 223 (6): 534-7. PMID 16804825.
- Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177-9. PMID 16567279.
External links
Ophthalmologicals: antiglaucoma preparations and miotics (S01E) | |
|---|---|
| Sympathomimetics | Apraclonidine • Brimonidine • Clonidine • Dipivefrine • Epinephrine |
| Parasympathomimetics | Aceclidine • Acetylcholine • Carbachol • Demecarium • Echothiophate • Stigmine (Fluostigmine, Neostigmine, Physostigmine) • Paraoxon • Pilocarpine |
| Carbonic anhydrase inhibitors | Acetazolamide • Brinzolamide • Diclofenamide • Dorzolamide • Methazolamide |
| Beta blocking agents | Befunolol • Betaxolol • Carteolol • Levobunolol • Metipranolol • Timolol |
| Prostaglandin analogues | Bimatoprost • Latanoprost • Travoprost • Unoprostone |
| Other agents | Dapiprazole • Guanethidine |
Eicosanoids: prostaglandins | |
|---|---|
| Endogenous/series 2 | D2 - E2 (Dinoprostone) - F2 (Dinoprost) - H2 - I2 (Prostacyclin) |
| Prostaglandin analogues | E: Alprostadil - Enprostil - Misoprostol
F: Bimatoprost - Carboprost - Latanoprost - Travoprost I: Beraprost - Iloprost - Treprostinil |
